ResearcherTianjin Medical University Cancer Institute and HospitalNo recent work listed

Jian Hao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7637-009X; OpenAlex author ID A5102336618. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper

Papers 2

Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation. Co-author DOI 10.1038/srep32809 ↗
Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer. First author DOI 10.1097/md.0000000000001008 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xue Ling Yang · 2 shared papers, 2015–2016 · strength 0.12
- Paper Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphor… DOI 10.1038/srep32809 ↗
- Paper Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer. DOI 10.1097/md.0000000000001008 ↗
Xiong-Zhi Wu · 2 shared papers, 2015–2016 · strength 0.12
- Paper Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphor… DOI 10.1038/srep32809 ↗
- Paper Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer. DOI 10.1097/md.0000000000001008 ↗
Tong Zhou · 1 shared paper, 2016 · strength 0.06
- Paper Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphor… DOI 10.1038/srep32809 ↗
Chang Liu · 1 shared paper, 2015 · strength 0.06
- Paper Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer. DOI 10.1097/md.0000000000001008 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.